Various direct Wnt/β-catenin signaling target genes, including GLP1, PPARδ, TCF7L2, AXIN, and WISP1, and indirect effectors, such as PPARγ and C/EBPα, which are suppressed by WISP1, are involved in metabolic diseases and have been used as targets for the development of drugs34. This evidence concerns the gene GLP1R and metabolic disease.